{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "DKK", "exchange": "CXE", "shortName": "Zealand Pharma A/S", "longName": "Zealand Pharma A/S", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "market": "gb_market", "esgPopulated": false, "fullExchangeName": "Cboe UK", "financialCurrency": "DKK", "regularMarketOpen": 230.7, "averageDailyVolume3Month": 171, "averageDailyVolume10Day": 195, "fiftyTwoWeekLowChange": 144.8, "fiftyTwoWeekLowChangePercent": 1.9306667, "fiftyTwoWeekRange": "75.0 - 245.0", "fiftyTwoWeekHighChange": -25.199997, "fiftyTwoWeekHighChangePercent": -0.10285713, "fiftyTwoWeekLow": 75.0, "fiftyTwoWeekHigh": 245.0, "earningsTimestamp": 1683806400, "earningsTimestampStart": 1683806400, "earningsTimestampEnd": 1683806400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -20.75, "sharesOutstanding": 58351900, "bookValue": 15.852, "fiftyDayAverage": 228.412, "fiftyDayAverageChange": -8.6119995, "fiftyDayAverageChangePercent": -0.037703797, "twoHundredDayAverage": 178.987, "twoHundredDayAverageChange": 40.813004, "twoHundredDayAverageChangePercent": 0.22802217, "marketCap": 13129182208, "priceToBook": 13.865758, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "tradeable": false, "cryptoTradeable": false, "regularMarketChangePercent": 0.0, "regularMarketPrice": 219.8, "marketState": "POSTPOST", "firstTradeDateMilliseconds": 1681887600000, "priceHint": 2, "regularMarketChange": 0.0, "regularMarketTime": 1683726466, "regularMarketDayHigh": 219.8, "regularMarketDayRange": "219.8 - 219.8", "regularMarketDayLow": 219.8, "regularMarketVolume": 1744, "regularMarketPreviousClose": 219.8, "bid": 217.4, "ask": 0.0, "symbol": "ZEALC.XC"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Sydmarken 11", "address2": "SOeborg", "city": "Copenhagen", "zip": "2860", "country": "Denmark", "phone": "45 88 77 36 00", "fax": "45 88 77 38 98", "website": "https://www.zealandpharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.", "fullTimeEmployees": 196, "companyOfficers": [{"maxAge": 1, "name": "Mr. Adam Sinding Steensberg M.D.", "age": 48, "title": "Pres & CEO", "yearBorn": 1974, "fiscalYear": 2021, "totalPay": {"raw": 5146000, "fmt": "5.15M", "longFmt": "5,146,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Henriette  Wennicke", "age": 39, "title": "EVP & CFO", "yearBorn": 1983, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Ivan Mourits Moller", "age": 50, "title": "Exec. VP & COO", "yearBorn": 1972, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Mads  Kronborg", "title": "Head of Investor Relations & Communication", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Ravinder  Chahil", "age": 54, "title": "Sr. VP & Gen. Counsel", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Christina Sonnenborg Bredal", "age": 37, "title": "Sr. VP and Global Head of People & Organization", "yearBorn": 1985, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jens Damsgaard Mikkelsen M.D.", "title": "Head of Molecular Pharmacology", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Danilo  Verge", "title": "Head of Global Medical Affairs", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. David M. Kendall M.D.", "age": 61, "title": "Sr. VP & Chief Medical Officer", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Lykke  Romer", "title": "VP & Head of Fin. and Accounting", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 4, "boardRisk": 1, "compensationRisk": 9, "shareHolderRightsRisk": 1, "overallRisk": 4, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}